Jeong Seong Hyun
Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea.
Blood Res. 2022 Apr 30;57(S1):120-129. doi: 10.5045/br.2022.2022054.
Treatment of indolent lymphoma has improved significantly in recent decades since the advent of rituximab (anti-CD20 monoclonal antibody). Although, some patients with limited disease can be cured with radiation therapy alone, most patients experience disease progression and recurrence during follow-up despite early initiation of treatment. Thus, watch-and-wait is still regarded the standard for asymptomatic patients. Patients with indolent lymphoma have a significant heterogeneity in terms of tumor burden, symptoms (according to anatomical sites) and the need for instant therapy. Therefore, the initiation of treatment and treatment option should be decided with a clear goal in each patient according to the need for therapy and clinical benefits with the chosen treatment. In this review, we cover the current treatment of follicular lymphoma and marginal zone lymphoma.
自利妥昔单抗（抗CD20单克隆抗体）问世以来，近几十年来惰性淋巴瘤的治疗有了显著改善。尽管一些疾病局限的患者仅通过放射治疗即可治愈，但大多数患者即使早期开始治疗，在随访期间仍会出现疾病进展和复发。因此，观察等待仍被视为无症状患者的标准治疗方式。惰性淋巴瘤患者在肿瘤负荷、症状（根据解剖部位）以及立即治疗的需求方面存在显著异质性。因此，应根据治疗需求和所选治疗的临床获益，为每位患者明确目标后再决定治疗的启动和治疗方案。在本综述中，我们涵盖了滤泡性淋巴瘤和边缘区淋巴瘤的当前治疗方法。
